Telesis Bio

San Diego, United States Founded: 2013 • Age: 13 yrs
Online platform offering life sciences reagents and kits
Request Access

About Telesis Bio

Telesis Bio is a company based in San Diego (United States) founded in 2013.. Telesis Bio has raised $25 million across 2 funding rounds from investors including Oxford Finance, Broadoak Capital Partners and Novalis LifeSciences. Telesis Bio has completed 1 acquisition, including Eton Bioscience. Telesis Bio offers products and services including BioXp System, BioXp 3250 System, BioXp 9600 System, and Gibson SOLA. Telesis Bio operates in a competitive market with competitors including Amyris, Syngenta, AskBio, Quanterix and Ginkgo Bioworks, among others.

  • Headquarter San Diego, United States
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Telesis Bio, Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
    $27.51 M
    0.27
    as on Dec 31, 2023
  • Net Profit
    $-47.72 M
    1.54
    as on Dec 31, 2023
  • EBITDA
    $-31.05 M
    28.81
    as on Dec 31, 2023
  • Total Equity Funding
    $25 M (USD)

    in 2 rounds

  • Latest Funding Round
    $28 M (USD), Post-IPO

    May 31, 2023

  • Investors
  • Employee Count
    Employee Count
  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Telesis Bio

Telesis Bio is a publicly listed company on the OTC with ticker symbol TBIO in USA, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: OTC · Ticker: TBIO . Sector: Commercial services · USA

Products & Services of Telesis Bio

Telesis Bio offers a comprehensive portfolio of products and services, including BioXp System, BioXp 3250 System, BioXp 9600 System, and Gibson SOLA. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Fully automated tool for DNA and mRNA synthesis in research labs

Compact system for gene assembly and amplification processes

Scalable device for large-scale DNA workflows

Technique for efficient DNA fragment assembly in experiments

People of Telesis Bio
Headcount 50-200
Employee Profiles 15
Employee Profiles
People
Vinnie Nijor
Head Of Business Development
People
Krishna Kannan
Vice President, Product And Operations
People
Daniel Gibson
Chief Technology Officer
People
Eric Esser
President And CEO At Telesis Bio

Unlock access to complete

Funding Insights of Telesis Bio

Telesis Bio has successfully raised a total of $25M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $28 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Post-IPO — $28.0M
  • First Round

    (09 Sep 2019)

  • Investors Count 5
Date Amount Transaction Name Valuation Lead Investors Investors
May, 2023 Amount Post-IPO - Telesis Bio Valuation

investors

Sep, 2019 Amount Series A - Telesis Bio Valuation Northpond Ventures
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Telesis Bio

Telesis Bio has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Oxford Finance, Broadoak Capital Partners and Novalis LifeSciences. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Investment and advisory services are provided for life sciences.
Founded Year Domain Location
Venture capital firm investing in life sciences & tech sectors
Founded Year Domain Location
Venture debt firm focused on the life sciences sector
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Telesis Bio

Telesis Bio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Eton Bioscience. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
DNA sequencing products and genomic services are developed and provided.
2003
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Telesis Bio

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Telesis Bio Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Telesis Bio

Telesis Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amyris, Syngenta, AskBio, Quanterix and Ginkgo Bioworks, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of renewable products for industrial solutions
domain founded_year HQ Location
Crop protection solutions and hybrid seeds are provided for farming.
domain founded_year HQ Location
Gene and protein therapies are developed for treating various diseases.
domain founded_year HQ Location
Assay kits for ultra-sensitive biomarker detection are developed.
domain founded_year HQ Location
Gene editing-based cultured ingredients are provided for agriculture.
domain founded_year HQ Location
Yeast cells are genetically engineered to produce medicinal products.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Telesis Bio

Frequently Asked Questions about Telesis Bio

When was Telesis Bio founded?

Telesis Bio was founded in 2013 and raised its 1st funding round 6 years after it was founded.

Where is Telesis Bio located?

Telesis Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.

Who is the current CEO of Telesis Bio?

Todd R Nelson is the current CEO of Telesis Bio.

Is Telesis Bio a funded company?

Telesis Bio is a funded company, having raised a total of $25M across 2 funding rounds to date. The company's 1st funding round was a Series A of $25M, raised on Sep 09, 2019.

What is the annual revenue of Telesis Bio?

Annual revenue of Telesis Bio is $27.51M as on Dec 31, 2023.

What does Telesis Bio do?

Online platform offering life sciences reagents and kits. The companys products include the BioXp system, BioXp kits, and Benchtop reagents. Also, it develops vaccines, therapeutics, and diagnostics to combat the COVID-19 pandemic.

Who are the top competitors of Telesis Bio?

Telesis Bio's top competitors include Syngenta, Antheia and Amyris.

What products or services does Telesis Bio offer?

Telesis Bio offers BioXp System, BioXp 3250 System, BioXp 9600 System, and Gibson SOLA.

Is Telesis Bio publicly traded?

Yes, Telesis Bio is publicly traded on OTC under the ticker symbol TBIO.

How many acquisitions has Telesis Bio made?

Telesis Bio has made 1 acquisition, including Eton Bioscience.

Who are Telesis Bio's investors?

Telesis Bio has 5 investors. Key investors include Oxford Finance, Broadoak Capital Partners, Novalis LifeSciences, Northpond Ventures, and M 185 Corporation.

What is Telesis Bio's ticker symbol?

The ticker symbol of Telesis Bio is TBIO on OTC.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available